Physician profile
John T Heidrick
NPI 1447252754
$17,486.69
in general payments reported to CMS, 2019-2025
62 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $3,022 · 2021: $3,208 · 2022: $2,856 · 2023: $2,424 · 2024: $2,149 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,214.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,491.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,498.05 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $1,301.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,159.68 | 2019-2025 | |
| Amarin Pharma, INC. | $1,113.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $773.32 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $748.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $603.86 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Supernus Pharmaceuticals, INC. | $400.83 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $393.36 | 2019-2022 | |
| Pfizer INC. | $392.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $372.57 | 2022-2025 | |
| Allergan, INC. | $318.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $300.15 | 2020-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $289.87 | 2021-2025 | Rexulti |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Heidrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.